Great day indeed !!! Excellent Volume, maybe Mutual Funds?? ALSO....
Aviron CEO J. Leighton Read Named Life Sciences
Entrepreneur of the Year
PR Newswire - June 29, 1998 12:42
AVIR %MTC V%PRN P%PRN
MOUNTAIN VIEW, Calif., June 29 /PRNewswire/ -- Aviron (Nasdaq: AVIR) today
announced that J. Leighton Read, M.D., Chairman and CEO of Aviron, has been
named Northern California Life Sciences Entrepreneur of the Year. This prestigious
award was presented to Dr. Read on June 26, as part of the National Entrepreneur of
the Year awards program founded by the professional services firm of Ernst & Young.
The program honors and recognizes life science and other entrepreneurs who have
demonstrated excellence and extraordinary success in such areas as innovations,
financial performance and personal commitment to their businesses and communities.
"Entrepreneurship is a team sport, so this award recognizes the many people of Aviron
whose hard work has contributed to our success," said Dr. Read. "I am proud to be
part of the Aviron team and to receive this award on their behalf," said J. Leighton
Read, M.D., chairman and chief executive officer.
An independent panel of judges selected the Northern California award recipients from
80 nominations obtained from the regional business community. As a recipient of the
1998 award, Dr. Read is now eligible for the National Entrepreneur of the Year award,
which will be decided in November.
Aviron is a biopharmaceutical company based in Mountain View, CA, whose strategy
is to focus on the prevention of disease. The company's goal is to develop vaccines to
prevent a wide range of infections that affect the general population, providing a
cost-effective means of addressing a number of major diseases. The majority of
Aviron's the company's products under development are live vaccines against viral
infections, including influenza, parainfluenza (PIV-3), cytomegalovirus (CMV), genital
herpes (HSV-2) and respiratory syncytial virus (RSV). Aviron is also developing -- in
collaboration with SmithKline Beecham Biologicals -- a subunit vaccine against
Epstein-Barr Virus (EBV) infection, a major cause of infectious mononucleosis.
This press release contains forward-looking statements. Actual results may differ
materially from those suggested here. Additional information concerning factors that
could cause such a difference is contained in Aviron's Annual Report on Form 10-K for
the year ended December 31, 1997.
SOURCE Aviron
/CONTACT: media, John Bluth of Fleishman-Hillard, 212-453-2000, for
Aviron; or investors, Fred Kurland or Lyn Christenson of Aviron, 650-919-6500/
/Company News On-Call: prnewswire.com or fax, 800-758-5804,
ext. 114000/ |
